IHC analysis also revealed a synchronous reduction of FXR and downstream targets, namely, IL-6, IL-6ST, and p-STAT3 (Tyr705), in Z-GS-treated NSCLC tumors in vivo. The gene discussed is IL6; the disease is non-small cell lung carcinoma.